PF-07260437
PF-07260437 is a bispecific monoclonal antibody targeting B7-H4 and CD3, with Kd values of 63.5 nM and 66.75 nM against human and cynomolgus monkey CD3, respectively. PF-07260437 simultaneously binds B7-H4 on tumor cells and the CD3ε subunit in the T cell receptor complex, forming a tumor cell-bispecific antibody-T cell trimer. This process establishes an immune synapse and initiates non-MHC-dependent T cell activation, proliferation, and release of cytotoxic molecules such as granzyme B to kill tumor cells. PF-07260437 can be used in research related to advanced or metastatic breast cancer, ovarian cancer, and endometrial cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MX1 | EC50 |
0.062 nM
|
Significantly inhibits tumor cell proliferation.
Significantly inhibits tumor cell proliferation.
|
40366350 |
| MDA-MB-468 | EC50 |
0.512 nM
|
Significantly inhibits tumor cell proliferation.
Significantly inhibits tumor cell proliferation.
|
40366350 |
| HCC1954 | EC50 |
0.797 nM
|
Significantly inhibits tumor cell proliferation.
Significantly inhibits tumor cell proliferation.
|
40366350 |
| T47D | EC50 |
0.762 nM
|
Significantly inhibits tumor cell proliferation.
Significantly inhibits tumor cell proliferation.
|
40366350 |
| MDA-MB-453 | EC50 |
15.206 nM
|
Significantly inhibits tumor cell proliferation.
Significantly inhibits tumor cell proliferation.
|
40366350 |
In Vitro
PF-07260437 (0.1 μM-1 mM; 2 h) exhibits dose-dependent targeted binding activity in MX-1, HEK-293-hB7-H4 cells, and primary human/cynomolgus monkey T cells, with an affinity of 63.5 nM for human CD3 and 66.75 nM for cynomolgus monkey CD3[1].
PF-07260437 (0.1 μM-1 mM) exerts T cell-mediated cytotoxicity in MX-1, MDA-MB-468, MDA-MB-453, HCC-1954 and T-47D cells co-cultured with T cells at an E:T ratio of 2.5:1, and its EC50 value is negatively correlated with B7-H4 receptor density (R2 = 0.8045)[1].
PF-07260437 (1 μM-1 mM; 2-6 days) exerts no direct inhibitory effect on tumor cell proliferation in T-47D, HCC-1954 and MX-1 cells in the absence of T cells[1].
PF-07260437 induces activated T cells co-cultured with B7-H4-expressing breast cancer cells to release IFN-γ, IL-10, IL-2, and TNF-α in a B7-H4-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
PF-07260437 (1.5 ng/kg-0.5 mg/kg; i.v.; once weekly for three doses; approximately 25 days) dose-dependently and significantly inhibits tumor growth in orthotopic mammary fat pad xenograft NSG mouse models implanted with HCC-1954[1].
PF-07260437 (0.5 mg/kg; i.v.; once weekly, administered on days 7 and 14; observation for 35 days) induces complete tumor regression in an adoptively transferred T-47D (HR+HER2-) subcutaneous xenograft NSG mouse model[1].
PF-07260437 (1.5 ng/kg-0.5 mg/kg; i.v. or s.c.; once weekly for 3 doses; 35 days) induces complete tumor regression in an adoptively transferred MX-1-Luc subcutaneous xenograft NSG mouse model[1].
PF-07260437 (0.01-0.5 mg/kg; i.v. or s.c.; once weekly for 3 doses; within 25 days) dose-dependently inhibits tumor growth in NSG mouse models implanted with a variety of breast cancer PDXs (e.g., PDX-BRX-11380, PDX-BRX-24301, PDX-BRX-26305)[1].
PF-07260437 (0.5 mg/kg; s.c.; once weekly; 60 days) exhibits synergistic tumor-shrinking activity when combined with Fulvestrant (HY-13636) and Palbociclib (HY-50767) in a mouse model of adoptive transfer ZR-75-1 xenografts[1].
PF-07260437 (0.5 mg/kg; s.c.; single dose; 60 days), in combination with anti-PD-1 treatment, exhibits synergistic activity in enhancing anti-tumor effects and increasing T-cell infiltration in a humanized CD3ε-transgenic, immunocompetent mouse model orthotopically implanted with human B7-H4-expressing E0771 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Immunodeficient NSG female mice were subcutaneously inoculated with the human triple-negative breast cancer (TNBC) cell line MDA-MB-468, and received an intravenous injection of untreated human PBMCs 6 days prior to treatment initiation to establish an immune-reconstituted model[1]
-
Dosage:0.02, 0.04, 0.1, 0.5, 3 mg/kg
-
Administration:i.v.; once weekly on days (3 doses total); treated and monitored up to approximately day 25.
-
Result:Exhibited significant dose-dependent anti-tumor activity, achieving 133% tumor growth inhibition (TGI) at doses as low as 0.04 mg/kg.
-
Animal Model:NSG female mice were orthotopically inoculated in the mammary fat pad with the human HER2+ breast cancer cell line HCC-1954, and received an intravenous injection of human PBMCs 6 days prior to treatment initiation.[1]
-
Dosage:0.0015, 0.005, 0.05, 0.5 mg/kg
-
Administration:i.v.; once weekly on days (3 doses total); treated and monitored up to approximately day 25.
-
Result:Induced significant and dose-dependent tumor growth inhibition.
-
Animal Model:NSG mice, supplemented with a 90-day release estradiol pellet, were subcutaneously inoculated with the human HR+HER2- breast cancer cell line T-47D, and received an intravenous injection of adoptively transferred in vitro expanded human T cells 24 hours after the first dose[1]
-
Dosage:0.5 mg/kg
-
Administration:i.v.; once weekly on days (3 doses total); treated and monitored up to day 35
-
Result:Induced complete tumor regression in all mice with no tumor regrowth observed by day 35.
-
Animal Model:NSG mice were subcutaneously inoculated with the luciferase-expressing human TNBC cell line MX-1-Luc, and received an intravenous injection of adoptively transferred in vitro expanded human T cells 24 hours after the first dose[1]
-
Dosage:0.0015 (i.v.), 0.01, 0.05, 0.5 mg/kg (IV and s.c.)
-
Administration:i.v. or s.c.; once weekly (3 doses total); treated and monitored up to day 35
-
Result:Led to complete tumor regression at 0.05 mg/kg and 0.5 mg/kg doses (via both IV and SC routes), and sustained anti-tumor activity with no tumors growing back by day 35.
-
Animal Model:NSG mice were subcutaneously implanted in the flank with patient-derived breast cancer tissue fragments (PDX-BRX-11380, PDX-BRX-24301, PDX-BRX-26305), and received an intravenous injection of human PBMCs 6 days prior to treatment initiation.[1]
-
Dosage:0.01, 0.07, 0.5 mg/kg
-
Administration:i.v. or s.c.; once weekly (3 doses total); treated and monitored up to day 20-25
-
Result:Induced dose-dependent tumor growth inhibition, achieving over 100% tumor growth inhibition (TGI) at the 0.5 mg/kg dose.
-
Animal Model:Estradiol-supplemented NSG mice were subcutaneously inoculated with the human HR+ breast cancer cell line ZR-75-1[1]
-
Dosage:0.5 mg/kg (combined with Fulvestrant 10 mg/kg and Palbociclib 10 mg/kg)
-
Administration:s.c.; once weekly (Fulvestrant and Palbociclib schedules were maintained); treated and monitored up to day 60.
-
Result:Induced synergistic tumor shrinkage and regression effects, and upregulated immune checkpoint genes (PD-L1, PD-1, etc.) in the tumor microenvironment when combined with standard-of-care therapies (fulvestrant and palbociclib).
-
Animal Model:Immunocompetent mice, genetically engineered to express the human CD3ε transgene, were orthotopically inoculated in the mammary fat pad with the murine breast cancer cell line E0771-hB7-H4 stably expressing human B7-H4[1]
-
Dosage:0.5 mg/kg (combined with a surrogate murine anti-PD-1 antibody 10 mg/kg)
-
Administration:s.c.; single dose; anti-PD-1 antibody was i.p. every 3 days for 6 doses; treated and monitored up to day 60.
-
Result:Significantly enhanced synergistic anti-tumor activity (106% TGI) and led to a substantial increase in intratumoral CD3 and CD8 T-cell infiltration 9 days post-treatment when combined with an anti-PD-1 antibody.
Chemical Information
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PF-07260437 Related Classifications
HY-P992524 Related Classifications
Powered by Bioz